News

Kepler Capital Remains a Buy on Novo Nordisk (0QIU)
In a report released on April 22, David Evans from Kepler Capital maintained a Buy rating on Novo Nordisk (0QIU – Research Report), with a ...
‘Time to Make a Warren Buffett Move,’ Says Top Investor About Novo Nordisk Stock
Along with the rest of the market, Novo Nordisk (NYSE:NVO) has been sinking this year – with losses approaching 30% ...